Carl Dambkowski Sells 2,725 Shares of Apogee Therapeutics Inc. (NASDAQ:APGE) Stock

Key Points

• Insider Carl Dambkowski sold 2,725 shares of Apogee Therapeutics stock on August 6th for a total of $102,950.50, reducing his ownership by 1.14%.
• Apogee Therapeutics reported an EPS of ($0.95) for the last quarter, surpassing estimates by $0.24, with analysts projecting an average EPS of ($3.09) for the current fiscal year.
• Analysts have set optimistic price targets for Apogee Therapeutics, ranging from $90.00 to $116.00, with a consensus rating of "Buy" based on current market performance.

Apogee Therapeutics Inc. (NASDAQ:APGE - Get Free Report) insider Carl Dambkowski sold 2,725 shares of Apogee Therapeutics stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $37.78, for a total transaction of $102,950.50. Following the completion of the transaction, the insider directly owned 236,273 shares in the company, valued at $8,926,393.94. This represents a 1.14% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Carl Dambkowski also recently made the following trade(s):

• On Wednesday, July 2nd, Carl Dambkowski sold 10,090 shares of Apogee Therapeutics stock. The shares were sold at an average price of $45.09, for a total value of $454,958.10.
• On Wednesday, June 4th, Carl Dambkowski sold 2,725 shares of Apogee Therapeutics stock. The stock was sold at an average price of $36.96, for a total transaction of $100,716.00.

Apogee Therapeutics Price Performance

Shares of NASDAQ:APGE traded down $0.61 during mid-day trading on Friday, reaching $35.39. 622,255 shares of the company were exchanged, compared to its average volume of 676,257. The firm has a market cap of $1.63 billion, a price-to-earnings ratio of -9.83 and a beta of 1.43. Apogee Therapeutics Inc. has a 1 year low of $26.20 and a 1 year high of $63.50. The firm's 50-day simple moving average is $40.18 and its 200 day simple moving average is $38.03.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.95) EPS for the quarter, topping the consensus estimate of ($1.19) by $0.24. On average, research analysts forecast that Apogee Therapeutics Inc. will post -3.09 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. BTIG Research upped their target price on Apogee Therapeutics from $100.00 to $115.00 and gave the company a "buy" rating in a research report on Monday, July 7th. Guggenheim reaffirmed a "buy" rating and issued a $116.00 price target on shares of Apogee Therapeutics in a research note on Wednesday, July 2nd. Citigroup reissued a "buy" rating on shares of Apogee Therapeutics in a research note on Monday, July 7th. Finally, Wedbush reissued an "outperform" rating and set a $90.00 price target on shares of Apogee Therapeutics in a research report on Monday, July 7th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $99.00.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in APGE. Ameriprise Financial Inc. purchased a new stake in Apogee Therapeutics during the 4th quarter worth approximately $259,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Apogee Therapeutics by 4.1% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,835 shares of the company's stock worth $1,078,000 after acquiring an additional 931 shares in the last quarter. Rhumbline Advisers grew its stake in shares of Apogee Therapeutics by 3.2% in the first quarter. Rhumbline Advisers now owns 54,385 shares of the company's stock worth $2,032,000 after acquiring an additional 1,665 shares in the last quarter. BNP Paribas Financial Markets purchased a new stake in shares of Apogee Therapeutics during the fourth quarter worth $219,000. Finally, Bank of New York Mellon Corp raised its stake in shares of Apogee Therapeutics by 93.3% in the first quarter. Bank of New York Mellon Corp now owns 214,231 shares of the company's stock valued at $8,004,000 after acquiring an additional 103,404 shares in the last quarter. Hedge funds and other institutional investors own 79.04% of the company's stock.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.